Buy Tirzepatide 30mg

1. 1.
   Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).” New England Journal of Medicine, 2022. https://doi.org/10.1056/NEJMoa2206038
2. 2.
   Aronne LJ, Horn DB, le Roux CW, et al. “Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).” New England Journal of Medicine, 2025. https://doi.org/10.1056/NEJMoa2416394
3. 3.
   Frías JP, Davies MJ, Rosenstock J, et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).” New England Journal of Medicine, 2021. https://doi.org/10.1056/NEJMoa2107519
4. 4.
   Rosenstock J, Wysham C, Frías JP, et al. “Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.” The Lancet, 2021. https://doi.org/10.1016/S0140-6736(21)01324-6
5. 5.
   Heise T, Mari A, DeVries JH, et al. “Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes.” The Lancet Diabetes & Endocrinology, 2022. https://doi.org/10.1016/S2213-8587(22)00085-7
6. 6.
   Malhotra A, Grunstein RR, Fietze I, et al. “Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA).” New England Journal of Medicine, 2024. https://doi.org/10.1056/NEJMoa2404881
7. 7.
   Wilson JM, Nikooienejad A, Robins DA, et al. “The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.” Diabetes, Obesity and Metabolism, 2020. https://doi.org/10.1111/dom.14174

Research cited is published, peer-reviewed literature. Products sold for laboratory research use only. Not medical advice.